Observational studyEuropean geriatric medicine2024
The possible interaction between tryptophan and its metabolites with delirium in older patients with critical illnesses.
Observational study in European geriatric medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe present study aimed to investigate the relationship between delirium and tryptophan and its metabolites in critically ill older patients.
methodsThis prospective and observational study was conducted on patients who were > 60 years of age and hospitalized for at least 24 h at the internal medicine ICU in the tertiary health care unit (n = 120). All consecutively selected patients were evaluated for delirium at the baseline and follow-up period at the bedside by an intensive care specialist. At the end of the 24 h follow up, the patients were divided into two groups (with and without delirium). Clinical properties and tryptophan (TRP) and its metabolites [kynurenine (KYN), kynurenic acid (KYNA), quinolinic acid (QA), 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3HAA)] were compared between groups.
resultsThe median age of the patients was 79.5 (62-95) years and 53.3% were female. The median age and CCI score were significantly higher among patients with delirium than in those without delirium (P = 0.001 and 0.031, respectively). The level of TRP was significantly (borderline) decreased among patients with delirium (P = 0.056). The KYN/TRP and QA/TRP ratios were statistically and significantly higher in patients with delirium than those without (P < 0.001 and P = 0.016, respectively). The best predictive values for detecting delirium were calculated as ≤ 14,100 ng/mL for TRP (AUC: 0.601, P = 0.052), > 1.12 for KYN/TRP ratio (AUC: 0.704, P < 0.001), and > 0.75 for QA/TRP ratio (AUC: 0.627, P = 0.013). The QA/TRP ratio showed independent and borderline significant association with being delirium in multivariable regression analysis (Odds ratio: 2.007, P = 0.066).
conclusionThis study demonstrated that tryptophan and its metabolites obtained within the first 24 h of ICU admission might have predictive value for determining high-risk older patients for delirium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.